Advertisement

Nektar Therapeutics NKTR

Set alert

Price alert · NKTR

All alert types
38.87 USD -0.31 -0.79%

At close · Oct 30

38.50 -0.37 -0.95%

After hours · Oct 30, 5:19 PM ET

Bid
38.85 × 1
Ask
38.93 × 1
38.00 Day range 39.30
35.12 52-week range 100.35
YTD
-8.07%
1 year
-38.11%
Open
38.92
Prev close
39.18
Mkt cap
1.33B
Vol
600.97K
Avg vol
1.10M
EPS
-18.96
P/E
0.00
Div yield
0.00%
More statistics
Low
38.00
High
39.30
Forward P/E
-3.77
Beta
1.27
Short ratio
3.62
Inst. own
107.23%
Dividend
0.00
Ex-div date
Earnings
Nov 12, 2026
50-d avg
56.40
200-d avg
64.99
1y target
133.08

MAX chart

Chart tools
Interval

Events in this range
  • Aug 7, 2025Earnings: -2.95; estimate -3.02756; surprise 2.56%
  • Nov 6, 2025Earnings: -1.85; estimate -2.85; surprise 35.09%
  • May 7, 2026Earnings: -1.82; estimate -1.58235; surprise -15.02%
  • Oct 2, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (128)
NameDateAgo
MACD: Sell SignalOct 29, 20262 days ago
SMA: BearishSep 1, 20262 months ago
SMA: BullishJun 1, 20251 year ago
SMA: BullishJun 1, 20251 year ago
SMA: BearishNov 1, 20242 years ago
SMA: BullishFeb 1, 20242 years ago
RSI: OversoldFeb 1, 20233 years ago
MACD: Buy SignalJan 1, 20233 years ago
RSI: OversoldDec 1, 20223 years ago
MACD: Sell SignalJan 1, 20224 years ago
SMA: BearishMay 1, 20215 years ago
SMA: BullishJan 1, 20215 years ago
MACD: Buy SignalDec 1, 20205 years ago
SMA: BearishAug 1, 20206 years ago
SMA: BullishMay 1, 20206 years ago
SMA: BearishFeb 1, 20197 years ago
SMA: BullishJan 1, 20197 years ago
SMA: BearishDec 1, 20187 years ago
MACD: Sell SignalSep 1, 20188 years ago
SMA: BearishJun 1, 20188 years ago
RSI: OverboughtNov 1, 20179 years ago
SMA: BullishMar 1, 20179 years ago
SMA: BullishMar 1, 20179 years ago
MACD: Buy SignalMar 1, 20179 years ago
MACD: Sell SignalNov 1, 201610 years ago
SMA: BearishOct 1, 201610 years ago
SMA: BearishOct 1, 201610 years ago
MACD: Buy SignalApr 1, 201610 years ago
SMA: BullishMar 1, 201610 years ago
SMA: BullishMar 1, 201610 years ago
SMA: BearishFeb 1, 201610 years ago
SMA: BearishFeb 1, 201610 years ago
MACD: Sell SignalFeb 1, 201610 years ago
MACD: Buy SignalDec 1, 201510 years ago
SMA: BullishNov 1, 201511 years ago
SMA: BullishNov 1, 201511 years ago
SMA: BearishAug 1, 201511 years ago
SMA: BullishJun 1, 201511 years ago
SMA: BearishMar 1, 201511 years ago
MACD: Sell SignalMar 1, 201511 years ago
SMA: BearishFeb 1, 201511 years ago
SMA: BullishOct 1, 201412 years ago
SMA: BearishSep 1, 201412 years ago
SMA: BullishAug 1, 201412 years ago
MACD: Buy SignalAug 1, 201412 years ago
SMA: BearishJul 1, 201412 years ago
MACD: Sell SignalJul 1, 201412 years ago
SMA: BullishJun 1, 201412 years ago
SMA: BearishMay 1, 201412 years ago
SMA: BullishNov 1, 201313 years ago
SMA: BearishOct 1, 201313 years ago
SMA: BullishFeb 1, 201313 years ago
SMA: BullishJan 1, 201313 years ago
SMA: BearishNov 1, 201214 years ago
SMA: BearishOct 1, 201214 years ago
SMA: BullishSep 1, 201214 years ago
MACD: Buy SignalJun 1, 201214 years ago
SMA: BullishFeb 1, 201214 years ago
SMA: BearishMay 1, 201115 years ago
SMA: BullishApr 1, 201115 years ago
SMA: BearishMar 1, 201115 years ago
MACD: Sell SignalJan 1, 201115 years ago
SMA: BearishNov 1, 201016 years ago
RSI: OverboughtMar 1, 201016 years ago
SMA: BullishJul 1, 200917 years ago
SMA: BullishFeb 1, 200917 years ago
SMA: BearishJan 1, 200917 years ago
SMA: BullishDec 1, 200817 years ago
SMA: BearishNov 1, 200818 years ago
SMA: BullishOct 1, 200818 years ago
MACD: Buy SignalOct 1, 200818 years ago
RSI: OversoldJun 1, 200818 years ago
SMA: BearishJul 1, 200620 years ago
MACD: Sell SignalJul 1, 200620 years ago
SMA: BearishJun 1, 200620 years ago
MACD: Buy SignalJan 1, 200620 years ago
SMA: BullishNov 1, 200521 years ago
SMA: BullishNov 1, 200521 years ago
SMA: BearishOct 1, 200521 years ago
SMA: BearishAug 1, 200521 years ago
MACD: Sell SignalAug 1, 200521 years ago
MACD: Buy SignalJul 1, 200521 years ago
SMA: BullishMay 1, 200521 years ago
MACD: Sell SignalMar 1, 200521 years ago
SMA: BearishJan 1, 200521 years ago
SMA: BullishNov 1, 200422 years ago
SMA: BearishJul 1, 200422 years ago
SMA: BullishSep 1, 200323 years ago
SMA: BullishApr 1, 200323 years ago
MACD: Buy SignalMar 1, 200323 years ago
SMA: BearishJan 1, 200323 years ago
SMA: BullishNov 1, 200224 years ago
SMA: BearishMay 1, 200125 years ago
SMA: BullishApr 1, 200125 years ago
SMA: BearishMar 1, 200125 years ago
MACD: Sell SignalFeb 1, 200125 years ago
SMA: BearishJan 1, 200125 years ago
SMA: BullishDec 1, 200025 years ago
SMA: BearishNov 1, 200026 years ago
RSI: OverboughtJun 1, 200026 years ago
RSI: OverboughtJan 1, 200026 years ago
MACD: Buy SignalDec 1, 199926 years ago
SMA: BullishNov 1, 199927 years ago
SMA: BullishNov 1, 199927 years ago
SMA: BearishOct 1, 199927 years ago
SMA: BearishOct 1, 199927 years ago
SMA: BullishAug 1, 199927 years ago
SMA: BullishAug 1, 199927 years ago
SMA: BearishJun 1, 199927 years ago
SMA: BearishMay 1, 199927 years ago
SMA: BullishApr 1, 199927 years ago
SMA: BearishFeb 1, 199927 years ago
SMA: BullishNov 1, 199828 years ago
SMA: BearishOct 1, 199828 years ago
SMA: BullishSep 1, 199828 years ago
SMA: BullishSep 1, 199828 years ago
SMA: BearishAug 1, 199828 years ago
SMA: BearishJun 1, 199828 years ago
MACD: Sell SignalJun 1, 199828 years ago
SMA: BullishMay 1, 199828 years ago
SMA: BearishMar 1, 199828 years ago
RSI: OverboughtNov 1, 199729 years ago
RSI: OverboughtSep 1, 199729 years ago
RSI: OverboughtJun 1, 199729 years ago
SMA: BullishJan 1, 199729 years ago
SMA: BearishSep 1, 199630 years ago
RSI: OverboughtMar 1, 199630 years ago
SMA: BullishAug 1, 199531 years ago

Key statistics

Market cap
1.33B
Enterprise value
789.32M
Trailing P/E
0.00
Forward P/E
-3.77
PEG ratio
0.31
Price / sales
24.31
Price / book
1.47
EPS (TTM)
-18.96
Beta
1.27
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-287.84%
Revenue (TTM)
54.59M
Revenue growth
-9.30%
Free cash flow
-134.77M
Total cash
684.34M
Total debt
135.93M
Return on equity
-35.76%
Shares outstanding
34.14M
Short % of float
22.59%
50-day average
56.40
200-day average
64.99

Analyst view

Consensus: buy

Buy
Price target (mean) 133.08 +242.4% upside
Target (low)
50.00
Target (mean)
133.08
Target (high)
192.00
Ratings (0m) 15 11 buy · 4 hold · 0 sell
  • Strong buy1
  • Buy10
  • Hold4
  • Sell0
  • Strong sell0

Next earnings

Nov 12, 2026

Expected Nov 12, 2026. Consensus EPS estimate -2.11.

Earnings history

Financials — quick view

All financials
NKTR Revenue — quarterly 10.13M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
NKTR Net income — quarterly -40.62M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
NKTR EPS — quarterly -1.23
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

NKTR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2026Sep 30, 2026-2.07———
Aug 13, 2026Jun 30, 2026-1.97-1.23+0.74+37.56%
May 7, 2026Mar 31, 2026-1.58-1.82-0.24-15.02%
Mar 12, 2026Dec 31, 2025-2.47-1.78+0.69+28.05%
Nov 6, 2025Sep 30, 2025-2.85-1.85+1.00+35.09%
Aug 7, 2025Jun 30, 2025-3.03-2.95+0.08+2.56%

Upgrades / downgrades

NKTR analyst upgrades and downgrades
DateFirmActionFromTo
Oct 12, 2026UBSinit—Neutral
Oct 12, 2026Leerink Partnersinit—Outperform
Oct 9, 2026BTIGreitBuyBuy
Oct 9, 2026Raymond Jamesinit—Market Perform
Oct 2, 2026HC Wainwright & Co.reitBuyBuy
Sep 28, 2026BTIGreitBuyBuy

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
nektar.com

News

Your note

Sign in to keep a note on NKTR — it syncs with the Stock Master app.

Insider holders

NKTR insider holders
InsiderRelationLatest transactionDateShares held
ROBIN HOWARD WChief Executive OfficerSaleAug 17, 202654,655
WILSON MARK ANDREWOfficerSaleNov 24, 202521,585
ZALEVSKY JONATHANOfficerSaleAug 17, 20269,570

Institution ownership

NKTR institution ownership
Holder% heldSharesValueReported
FMR, LLC14.84%5,067,920196.99MJun 29, 2026
Two Seas Capital Lp9.80%3,345,978130.06MSep 29, 2026
Blackrock Inc.8.62%2,941,851114.35MJun 29, 2026
BVF Inc.7.00%2,391,07592.94MJun 29, 2026
Vanguard Capital Management LLC4.38%1,496,84958.18MJun 29, 2026
Two Sigma Investments, LP3.52%1,202,00446.72MJun 29, 2026

Fund ownership

NKTR fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund5.42%1,850,47871.93MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.15%1,075,10841.79MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.86%975,22437.91MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.61%892,63734.70MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund1.47%500,35119.45MAug 30, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund1.24%424,55416.50MAug 30, 2026
Advertisement